Purpose One of the key immune cells involved in the pathogenesis of lung cancer is natural killer (NK) cells and these cells are novel targets for therapeutic applications in lung cancer. The purpose of this review is to summarize the current literature on lung cancer pathogenesis with a focus on the interaction between NK cells and smoking, how these factors are related to the pathogenesis of lung cancer and how NK cell-based immunotherapy effect lung cancer survival. 
Introduction
Cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases and 8.2 million cancer deaths reported in 2012 (World Health Organization 2012) . Lung cancer represents 13.2% of all newly diagnosed cancers in the US and the estimated number of deaths from pulmonary malignancies is 155,870 in 2017, showing the importance of implementing prevention and treatment strategies for this mortal disease (National Cancer Institute 2014). Former or current status of smoking is the main risk factor for the majority of diagnosed lung cancers (IARC Working Group on the Evaluation of Carcinogenic Risks to Humans 2004). Due to high smoking prevalence in Turkey, the incidence of lung cancer diagnosed in males (98/100,000) is almost two times higher than the incidence in the US (52.5/100,000) (Anton-Culver et al. 2016) .
Lung cancer mainly consists of two subtypes, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) and standard anti-cancer therapy includes chemotherapy, radiotherapy and/or surgery (World Health Organization 2012) . Prognosis of lung cancer depends on the staging and histological classification of the tumor as well as clinical factors. According to the report of Surveillance, Epidemiology, and End Results Program (SEER), National Institute of Health (NIH), only 18.1% of patients with lung cancer have survived 5 or more years after the diagnosis (National Cancer Institute 2014) . Various genetic mutations were reported in both SCLCs and NSCLCs. Recently, treatment strategies to target these mutations including activating mutations of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) translocations with encouraging results led these treatments to become incorporated into standard treatment algorithms (Morgensztern et al. 2015) . Additionally, the interaction between the immune system and lung cancer has also been studied for novel therapeutic strategies in lung cancer management such as cancer immunotherapy.
The growing understanding of immune mechanisms in lung cancer indicates highly complex immune interactions in each stage of lung cancer. One of the key immune cells in the tumor microenvironment is natural killer (NK) cells which can play an important role in initiating and promoting cancer. They are effective at the first line defence for tumor elimination and major functions include cytotoxicity and cytokine production which help to kill tumor cells (Deniz et al. 2013) . It was reported that peripheral NK cell cytotoxicity and interferon gamma (INF-γ) production was reduced in lung cancer patients (Platonova et al. 2011; Al Omar et al. 2011; Li Yang et al. 2016) . Furthermore, infiltration of the tumor tissue by NK cells was associated with good prognosis in lung cancer (Villegas et al. 2002) . However, there is still limited data regarding the effects of NK cells on lung cancer pathogenesis. We aim to provide a literature review on lung cancer pathogenesis with a focus on the role of NK cells in lung cancer development. The interaction between NK cells and smoking, how these factors are related to the pathogenesis of lung cancer and NK cell-based immunotherapy will also be discussed.
NK cells
NK cells constitute 10% of peripheral lymphocytes in human. They are present at a high frequency in the peripheral blood, lymph nodes, spleen, and bone marrow (Ferlazzo et al. 2004; Jonges et al 2001) and they can also migrate to inflammation sites due to different chemoattractants (Jonges et al 2001) . NK cells are important in both innate and adaptive immune system. They stimulate maturation of dendritic cells, and play a role in activation of monocytes and cytotoxic T cells (Deniz et al. 2013 ). In addition, cytokines produced by NK cells influence T helper (T H ) cell polarization, and activated NK cells either stimulate or inhibit B cells to produce immunoglobulin (Deniz et al. 2013) . NK cell markers are CD16 and CD56 which help the identification of NK cell subsets (Cooper et al. 2001) . Majority of human NK cells have low expressions of density expression of CD56 (CD56dim), and express high levels of CD16 (CD16bright). Another type of NK cell is called CD56bright which is further classified as CD16+ and CD16− subtypes. These two subsets of NK cells have different levels of cytotoxicity and cytokine production. CD56bright cells are the major subset in the secondary lymphoid organs, and can produce large amounts of cytokines. In contrast, CD56dim cells possess a strong cytolytic capacity, and secrete low levels of cytokines (Deniz et al. 2013; Poli et al 2009) .
The major functions of NK cells are cytotoxicity and cytokine production (Deniz et al. 2013) . Activated NK cells produce various cytokines, including IFN-γ, tumor necrosis factor alpha (TNF-α) and granulocyte-macrophage colonystimulating factor (GM-CSF) (Vivier et al. 2011) . IFN-γ maintains anti-tumor activity by inducing MHC I expression and activating CD8+ T cells to kill tumor cells (Marcus et al. 2014) . TNF-α can have direct cytotoxic activity by triggering caspase 8-mediated apoptosis (Peter and Krammer 2003) . NK cell-mediated lysis of the target cell occurs by the release of cytotoxic molecules perforin and granzymes A and B (Deniz et al. 2013 ). Cytotoxicity of NK cells can be explained through two mechanisms: natural cytotoxicity against tumor cells or virally infected cells in the absence of prior stimulation, and antibody-dependent cellular cytotoxicity against IgG-coated target cells (Deniz et al. 2013 ). NK cells express a variety of receptors such as activating receptors NKG2D; the natural killing receptors NKp30, NKp44, NKp46, and NKp80; the SLAM-family receptors and killer Ig-like receptors (KIR) families that transmit inhibitory signals when engaged by MHC I molecules expressed by target cells (Marcus et al. 2014) . Among various NK cell receptors, NKG2D receptor is unique since it recognizes antigens frequently expressed on different tumors, indicating the role of NK cells in tumor immune surveillance (Bauer et al. 1999) . Although NKG2D receptor-ligand interaction is effective to kill tumor cells, NK cells are also capable of destroying certain tumors which lacks ligands for NKG2D receptor. NKp30, NKp44 and NKp46 receptors linked to Immunoreceptor Tyrosine-based Activating Motif (ITAM)-bearing signaling adaptor molecules were proposed to be responsible for the recognition and destruction of tumors lacking NKG2D ligands (Pende et al. 2001) . KIR expression by NK cells also allows for recognition and elimination of tumor cells which lost class I MHC expression (Marcus et al. 2014 ).
NK cells and smoking
Cigarette smoking is a predominant etiologic factor for lung cancer (IARC Working Group on the Evaluation of 1 3
Carcinogenic Risks to Humans 2004) and the effect of cigarette smoking on immune cells has been investigated for decades. It has already been revealed that cigarette smoking impairs the immune defense (Sopori 2002) . In murine lung metastasis model, increased melanoma metastasis to the lungs was associated with exposure to cigarette smoke. Using RAG2 −/− (T and B cell deficient) and RAG2 −/− γ c −/− (NK cell, B and T cell deficient) mice, destructive effect of cigarette smoking on tumor immune surveillance were shown to be resulted from weakened NK cell activity. Cigarette smoking suppresses NK cell activation and NK cell dependent tumor immune surveillance (Lu et al. 2007 ). In murine chronic obstructive lung disease (COPD) model, NK cell functioning following smoke exposure was examined and smoke exposure was found to promote the expression of IFN-γ and CD107a in NK cells upon stimulation, and enhanced NK cell responses (Motz et al. 2010 ). Spleen cells from monkeys exposed to high dose (human equivalent of 3 packs/day) cigarette smoke had a significant reduction in their NK cell-mediated lytic activity and a decreased response to concanavalin A (Sopori et al. 1985) .
Previous observations on smoking-associated NK cell dysfunction were supported by in vitro studies. Cigarette smoke was reported to inhibit IFN-γ and TNF-α in human NK cells from non-smokers in vitro. Reduced cytotoxic activity in NK cells was also observed in smokers (Mian et al. 2008) . Cigarette smoke suppresses the induction of IL-15 and IL-15 mediated NK cell functions in human peripheral blood mononuclear cells (PBMCs) (Mian et al. 2009 ). Exposure of PBMCs from non-smoking individuals to smoke-conditioned media is associated with defective activation of IRF-3 and NF-kB in PBMCs (Mian et al. 2009 ). Exposure of PBMCs to cigarette smoke also was also found to be related with impaired NK cell cytolytic potential to kill K562 cancer cells through inhibition of IL-15 (Mian et al. 2009a, b, c) . In previous human studies, smoking caused a decrease in serum immunoglobulin concentrations together with a reduction of the absolute number of CD16+ NK-cells, especially in men smoking for more than 10 years (Moszczyński et al. 2001) . Another study investigating several immunological markers in pairs of healthy smoking and non-smoking monozygotic twins who shared similar environmental conditions and lifestyles demonstrated that smoking was associated with significant increases in the number of circulating leukocytes, neutrophils, T helper cells and B cells, and decreases in the number of NK cells and CD8+ T cells (Andreoli et al. 2015) . A study by Luppi et al. reported that the frequency of circulating NK cells was significantly decreased in early pregnancy of women who were light or heavy smokers compared to nonsmoker pregnant women (Luppi et al. 2007 ).
NK cells and lung cancer
NK cells produce cytolytic enzymes and cytokines, including granzyme B, perforin and IFN-γ which are essential to inhibit proliferation of lung cancer cells (Hodge et al. 2014 ). There is significantly reduced granzyme B production by NK cells from cancer tissue obtained by lung resection surgery when compared to non-cancer tissue (Castriconi et al. 2003) . Tumor cells also release immunosuppressive cytokines such as IL-10 or TGF-β which suppress NK cell function (Castriconi et al. 2003; Huang et al. 2014; Vita et al. 2000; Hatanaka et al. 2000; Schneider et al. 2011) . TGFβ1 has been shown to inhibit human NK-mediated anti-tumor cytotoxicity by selectively down-regulating the surface expression of NKp30 and NKG2D (Castriconi et al. 2003) . The expression of TGF-β1 protein in NSCLC tissue was significantly higher than in the normal lung tissue (Huang et al. 2014 ). IL-10 production was also increased in NSCLC tissue and an increased serum IL-10 concentration was correlated with reduced survival rate (Vita et al. 2000; Hatanaka et al. 2000) . IL-10 is mainly produced by regulatory T cells (Treg) and increased proportions of Tregs and decreased proportions of NK cells in tumor tissue have been reported in lung cancer (Schneider et al. 2011 ). There are specific molecules expressed on NK cells which can play a role in malignancies including lung cancers. T cell immunoglobulin-and mucin-domain-containing molecule-3 (Tim-3) is expressed on NK cells and plays an important role in regulating NKcell functions in cancer (Ndhlovu et al. 2012 ). Higher Tim-3 expression in CD3-CD56+ NK cells and CD3-CD56dim NK-cell subset was found to be associated with decreased NK cell cytotoxicity and poor prognosis in lung adenocarcinoma (Xu et al. 2015) . Furthermore, mRNA levels of the two major NK cell receptors, NCR1/NKp46 and NCR3/ NKp30 were reduced in NSCLC which was corraleted with poor overall and progression-free survival (Fend et al. 2016 ). The percentage of peripheral blood NK cells expressing the activating receptor NKp46 was significantly reduced in patients with NSCLC or SCLC compared to healthy donors (Al Omar et al. 2011) . Aforementioned studies underscore the role and importance of NK cells in the development of lung cancer and the effect of NK cells on the prognosis of and survival from this disease.
The survival of lung cancer patients was positively correlated with the degree of NK cell infiltration in lung cancer (Jin et al. 2014 ). For instance, there was a significant correlation between survival rates and the number of tumor infiltrating NK cells in patients with primary squamous cell lung carcinoma (Villegas et al. 2002) . Intratumoral NK functionality is essential in addition to the quantity of tumor infiltrating NK cells in the formation of immunosuppressive tumor microenvironment. Tumor microenvironment has been demonstrated to impair NK cell function locally, rendering them less tumoricidal. Platonova et al. reported that intratumoral NK cells had a decreased expression of a cluster of NKp30, NKp80, DNAM-1, CD16, and ILT2 receptors as compared to the NK cells from distal lung tissues or blood from the same patients or healthy donors (Platonova et al. 2011) . Moreover, intratumoral NK cells were defective in the ability to activate degranulation and IFN-γ production (Platonova et al. 2011) . In another study, CD56brightCD16-NK cell subset was mainly observed in tumor infiltrate. The cytolytic potential of these cells isolated from cancer tissues was lower than that of NK cells from peripheral blood or normal lung tissue (Carrega et al. 2008) . Factors that may cause decreased or dysfunctional NK cell activity in the tumor microenvironment are yet to be discovered. Interestingly, Esendagli et al. found that non-malignant tissue areas in NSCLC were also infiltrated by NK cells which shows strong cytotoxic activity ex vivo (Esendagli et al. 2008 ). Data coming from multiple studies may prove the protective role of NK cells in and around the tumor microenvironment.
NK cell-based immunotherapy in lung cancer
The influence of NK cells in the formation of immunosuppressive tumor microenvironment makes these cells a target for the development of treatments in cancer. These cells are increasingly considered as immunotherapeutic agents for the patients with different malignancies. Recent studies have been focused on proliferation of NK cell population, inhibition of NK cell suppression mechanisms and enhancement of NK cell target recognition (Lowry and Zehring 2017) . For instance, NK cellmediated antibody-dependent cell-mediated cytotoxicity could be enhanced using monoclonal antibodies with cytokines or with drugs that prevent both CD16 and NKG2D ligands shedding on tumor cells (Loza and Perussia 2004; Romee et al. 2013; Boutet et al. 2009 ). Up to date, most of studies regarding NK cell-based adoptive immune therapy have performed in hematologic malignancies. However, there have been increasing data showing that NK cells can selectively recognize and kill cancer stem cells in solid tumors (Luna 2017) . In 2000, Kim et al. showed the fundamental role of NK cells in prevention of lung metastasis (Kim et al. 2000) . In the study of Tonn et al., the NK-92 cell line (CD56+/CD3−) was isolated from a patient with lymphoma, expanded with recombinant interleukin-2 and infused to patients with solid tumors/sarcomas. After the treatment, an anti-tumor effect was observed in75% of the patients with lung cancer (Tonn et al. 2013) . Additionally, Hiraki et al. demonstrated that IL-12 activation of peripheral blood mononuclear cells can increase the cytolytic activity of lung cancer cells when combined with IL-2 (Hiraki et al. 2002) . Furthermore, IL-15 is another therapeutic target which is a homeostatic factor and required for NK cell development.
Recently, a phase I open label, non-randomized dose escalation study of subcutaneous rhIL-15 was conducted in refractory solid tumor cancer patients including advanced metastatic melanoma, renal cell carcinoma, NSCLC and squamous cell head and neck carcinoma (Miller et al. 2017) . Subcutaneous rhIL-15 treatment produced substantial increases in circulating NK and CD8+ T cells which can prove the effectiveness of immunotherapies targeting NK cells and lead to more studies on the immunotherapy agents for different malignancies including lung cancer.
In a murine lung cancer model, Cui et al. revealed that mixed adoptive immunotherapy with NK and dendritic cells promoted NK cell activity without exogenous cytokines and this data may prove to be useful in lung cancer treatment (Cui et al. 2013) . Additionally, Zhang et al. studied the efficacy of adaptive transfer of NK and cytotoxic T-lymphocytes mixed effector cells in NSCLC patients (Zhang et al. 2014) . A prolonged overall survival was shown in patients after receiving NK cell-based immunotherapy. In a recent study of Lin et al., the clinical outcomes of cryosurgery combined with allogenic NK cell immunotherapy for the treatment of advanced NSCLC were improved with enhanced immune functions and quality of life (Lin et al. 2017) . Krause et al. investigated the effectiveness of autologous transfer of NK cells activated ex vivo by the 14 amino acid sequence (TKD) of heat shock protein 70 (Hsp70) plus low-dose IL-2 in one NSCLC patient and 11 colorectal cancer patients who had failed standard therapies (Krause et al. 2004 ). An increased lytic activity against Hsp70 membrane-positive tumor target cells was shown in 10 out of 12 patients with no severe toxicity after NK cell reinfusion. Moreover, an ongoing phase II randomized control trial has been recently testing the efficacy of targeted NK cell-based adoptive immunotherapy for the treatment of 90 patients with stage IIIA/B NSCLC after radiochemotherapy (NCT02118415) (Specht et al. 2014) . Efficacy of targeted NK cell-based adoptive immunotherapy was also tested in SCLC patients. Ding et al. investigated the efficacy and safety of cellular immunotherapy with autologous NK, γδT, and cytokine-induced killer cells as maintenance therapy for 29 SCLC patients (Ding et al. 2015) . Immunotherapy as the maintenance therapy prolonged the survival of patients with SCLC. In fact, the great majority of NK-based lung cancer treatment mechanisms were identified in murine models. There are a limited number of clinical and/or phase studies in the literature, summarized in Table 1 . However, NK cells remain to have a promising therapeutic potential for lung malignancies.
Conclusion
NK cells have been shown to play an important role in the control of effective immune responses against lung cancer. NK cells can kill cancer cells via direct cytotoxity, induction of apoptosis or IFN-γ secretion. Cigarette smoking suppresses NK cell activation and NK cell dependent tumor immune surveillance. Majority of studies investigating NK cells in animal cancer models concluded that NK cells can play an anti-neoplastic role in lung cancer. Increasing evidence suggests that improving NK cell functioning may induce tumor regression. Clinical trials on NK based novel therapies such as cytokines, NK-92 cell lines, allogenic NK cell immunotherapy have showed increased survival rates from lung cancer. However, current clinical evidence is not sufficient to support the use of these therapies for thetreatment of lung cancer. More clinical studies focusing on the role of NK cells in lung carcinogenesis are warranted to develop novel NK-based therapeutic approaches for lung cancer. Such immunological studies using NK cell-based approaches may change the structure and rules of lung cancer treatment in the future. 
